Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
An Open-label, Randomized, Teriparatide-controlled Study to Evaluate the Effect of Treatment with AMG 785 in Postmenopausal Women with Osteoporosis Previously Treated with Bisphosphonate Therapy
2012-002948-24Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of romosozumab in osteoporosis (2 arms), sponsored by Amgen. Primary endpoint: Percent change in total hip BMD at 12 months. Started Mar 2013; status: completed.
02
Drugs
romosozumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2012-002948-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002948-24.